Plasma thiol/disulphide homeostasis changes in patients with relapsing‐remitting multiple sclerosis

Abstract

Background: Multiple sclerosis (MS) is a neuroinflammatory disease and inflammation and oxidative stress play important roles in its pathology. Thiol/disulphide homeostasis (TDH) is a special oxidative stress biomarker that has been found to be affected in several disorders including MS. There is no study demonstrating the effects of attack status of the relapsing-remitting multiple sclerosis (RRMS) patients on TDH levels. Our aim was to determine TDH levels in three different periods of RRMS patients and healthy individuals. Methods:The study was carried out in 29 patients with RRMS without a prior attack in the last twelve months (MS Control), 21 RRMS patients having a clinical acute attack within the last week (MS relapse), 12 of 21 MS relapse patients one month after the onset of attack and following 1000 mg methylprednisolone for 7 days (MS Remission) and 30 age-and sex-matched healthy individuals. TDH status was determined using an automated spectrophotometric analysis method. TDH levels in all patient groups and control subjects were compared with each other. Results:The lowest native thiol, total thiol levels and native thiol/total thiol ratio were found in the MS relapse patients in comparison to the MS control, MS remission groups and healthy controls. In contrast, disulphide levels, disulphide/native thiol and disulphide/total thiol ratios were highest in the MS relapse group compared to the other patient groups and healthy subjects. Conclusion:Our findings indicate that increased oxidative stress in RRMS patients is reflected with decreased native and total thiol and increased disulphide levels. Since the formation of disulphide bonds is reversible, the progression of RRMS involving abnormal TDH may be controlled, converting disulphides to thiols. So, we suggest determining the dynamic TDH status as a novel and special biomarker in the diagnosis and prognosis of the RRMS patients. What's known• Multiple sclerosis (MS) is a neuroinflammatory disease and inflammation and oxidative stress play important roles in its pathology.• Like other inflammatory diseases, oxidative stress is associated with MS playing an important role in the pathogenesis of MS.

Neurocognitive impairment in multiple sclerosis and its association with thiol‐disulfide homeostasis and ischemia‐modified albumin

“…TDH has previously been studied in MS (Arslan et al, 2021;Calabrese et al, 2003;Ozben et al, 2021;Vural et al, 2019) Notes: Regression models were determined according to their partial least square regression results. Native Thiol, Total Thiol, Native Thiol/Total Thiol parameters were analyzed with smoking status in the models for naïve patients with RRMS, whereas Native Thiol, Total Thiol, Albumin parameters were analyzed with 25(OH)-D 3 and HDL-cholesterol levels in the models for RRMS patients with fingolimod therapy.…”

“…TDH has previously been studied in MS (Arslan et al, 2021; Calabrese et al, 2003; Ozben et al, 2021; Vural et al, 2019). Ozben et al have demonstrated that TDH has shifted toward the oxidized disulfide form in patients with RRMS (Ozben et al, 2021).…”

“…TDH has previously been studied in MS (Arslan et al, 2021; Calabrese et al, 2003; Ozben et al, 2021; Vural et al, 2019). Ozben et al have demonstrated that TDH has shifted toward the oxidized disulfide form in patients with RRMS (Ozben et al, 2021). The disulfide/total thiol ratio was significantly increased in relapse group compared to MS control group (patients with RRMS without an attack in the previous 12 months), which was in turn markedly higher than that of the remission group.…”

“…. Ozben et al have demonstrated that TDH has shifted toward the oxidized disulfide form in patients with RRMS(Ozben et al, 2021). The Binary logistic regression analysis results of cognitive impairment for the naïve patients with RRMS and RRMS patients on fingolimod therapy.…”

“…The possible role played by TDH in MS has been evaluated in a few research studies; however, information regarding MS subtypes is limited (Arslan et al, 2021;Calabrese et al, 2003;Ozben et al, 2021;Vural et al, 2019); while there is only one report regarding IMA in MS (Aydin et al, 2014). In contrast, the possible relationship between TDH, IMA status, and cognitive performance in MS has not been previously investigated.…”